Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 13/20 | 0.53 |
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.37 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1604225 | 1.00 | FFAR1 (0.53) | FFAR1NAAAPDCD1CD274CHRNB4 | |
| SCHEMBL1604998 | 0.85 | FFAR1 (0.73) | FFAR1 | |
| SCHEMBL1605000 | 0.85 | FFAR1 (0.73) | FFAR1 | |
| SCHEMBL1585387 | 0.84 | FFAR1 (0.74) | FFAR1CHRNB4CHRNA3 | |
| SCHEMBL1604336 | 0.84 | FFAR1 (0.62) | FFAR1 | |
| SCHEMBL1604334 | 0.84 | FFAR1 (0.62) | FFAR1 | |
| SCHEMBL1585384 | 0.84 | FFAR1 (0.74) | FFAR1CHRNB4CHRNA3 | |
| SCHEMBL12707992 | 0.78 | FFAR1 (0.64) | FFAR1 | |
| SCHEMBL1604449 | 0.77 | FFAR1 (0.51) | FFAR1 | |
| SCHEMBL1604447 | 0.77 | FFAR1 (0.51) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486005-B1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| US-8288404-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-16 | — | — | US | disclosed |
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR27 | FFAR1 37/4885NAAA 3658/4885PDCD1 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.